Literature DB >> 8130392

Novel Asn-linked oligosaccharides terminating in GalNAc beta (1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.) are present in recombinant human protein C expressed in human kidney 293 cells.

S B Yan1, Y B Chao, H van Halbeek.   

Abstract

Recombinant human Protein C (rHPC), expressed in human kidney 293 cells, has a higher anticoagulant activity than plasma HPC, while its in vivo circulatory half-life is essentially unaltered compared to that of the natural protein. In seeking to elucidate the molecular basis for the improved efficacy of the recombinant antithrombotic drug, we focused on the carbohydrate moiety of rHPC. Protein C is a heavily post-translationally modified serine protease with four N-glycosylation sites. Glycosyl composition analysis of rHPC revealed a 5-fold higher fucose content and a 2-fold lower sialic acid content compared to plasma HPC. In addition, we found that rHPC contains N-acetylgalactosamine (2.6 mol GalNAc/mol rHPC) in its Asn-linked oligosaccharides, while plasma HPC is devoid of GalNAc. The Asn-linked oligosaccharides of rHPC were released by N-glycanase and separated into 25 fractions by high-pH anion-exchange chromatography. The most abundant oligosaccharides were structurally characterized by glycosyl composition and linkage analysis, in conjunction with 1H-NMR spectroscopy at 600 MHz. The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.), in NeuAc alpha (2-->6)GalNAc beta (1-->4)GlcNAc beta (1-->.), and/or in GalNAc beta (1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.). Since the latter trisaccharide was first [Yan, S.B., Chao, B.Y. and Van Halbeek,H. (1992) J. Cell. Biochem., 16D, 151] observed in the Asn-linked oligosaccharides of rHPC derived from human kidney 293 cells, we propose to label the GalNAc beta-(1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.) terminal trisaccharide the PC-293 determinant. The PC-293-containing oligosaccharides may contribute to the higher anticoagulant activity of rHPC as compared to plasma HPC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8130392     DOI: 10.1093/glycob/3.6.597

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  21 in total

Review 1.  Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.

Authors:  E Grabenhorst; P Schlenke; S Pohl; M Nimtz; H S Conradt
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

2.  Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulation.

Authors:  C Kronman; B Velan; D Marcus; A Ordentlich; S Reuveny; A Shafferman
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

3.  The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc.

Authors:  Eric I Park; Yiling Mi; Carlo Unverzagt; Hans-Joachim Gabius; Jacques U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-14       Impact factor: 11.205

4.  Novel induction of alpha-lactalbumin-mediated lacdiNAc-R expression in vivo.

Authors:  S I Do; K Y Lee; H N Kim
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 5.  Schistosome glycoconjugates in host-parasite interplay.

Authors:  C H Hokke; A M Deelder
Journal:  Glycoconj J       Date:  2001-08       Impact factor: 2.916

6.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels.

Authors:  T Chitlaru; C Kronman; M Zeevi; M Kam; A Harel; A Ordentlich; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

7.  Molecular cloning and functional characterization of a Lepidopteran insect beta4-N-acetylgalactosaminyltransferase with broad substrate specificity, a functional role in glycoprotein biosynthesis, and a potential functional role in glycolipid biosynthesis.

Authors:  Nadia Vadaie; Donald L Jarvis
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

8.  N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

9.  Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012.

Authors:  Nancy Leymarie; Paula J Griffin; Karen Jonscher; Daniel Kolarich; Ron Orlando; Mark McComb; Joseph Zaia; Jennifer Aguilan; William R Alley; Friederich Altmann; Lauren E Ball; Lipika Basumallick; Carthene R Bazemore-Walker; Henning Behnken; Michael A Blank; Kristy J Brown; Svenja-Catharina Bunz; Christopher W Cairo; John F Cipollo; Rambod Daneshfar; Heather Desaire; Richard R Drake; Eden P Go; Radoslav Goldman; Clemens Gruber; Adnan Halim; Yetrib Hathout; Paul J Hensbergen; David M Horn; Deanna Hurum; Wolfgang Jabs; Göran Larson; Mellisa Ly; Benjamin F Mann; Kristina Marx; Yehia Mechref; Bernd Meyer; Uwe Möginger; Christian Neusüβ; Jonas Nilsson; Milos V Novotny; Julius O Nyalwidhe; Nicolle H Packer; Petr Pompach; Bela Reiz; Anja Resemann; Jeffrey S Rohrer; Alexandra Ruthenbeck; Miloslav Sanda; Jan Mirco Schulz; Ulrike Schweiger-Hufnagel; Carina Sihlbom; Ehwang Song; Gregory O Staples; Detlev Suckau; Haixu Tang; Morten Thaysen-Andersen; Rosa I Viner; Yanming An; Leena Valmu; Yoshinao Wada; Megan Watson; Markus Windwarder; Randy Whittal; Manfred Wuhrer; Yiying Zhu; Chunxia Zou
Journal:  Mol Cell Proteomics       Date:  2013-06-13       Impact factor: 5.911

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.